Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGE: Cangrelor Bridging in Patients Undergoing CABG
NCT00767507Phase 2Completed
- Sponsor
- The Medicines Company
- Start
- Oct 2008
- Primary completion
- Jun 2011
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of cangrelor in acute coronary syndrome (ACS), sponsored by The Medicines Company. Started Oct 2008; status: completed.
02
Drugs
cangrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00767507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00767507.